Improved CNS tolerability following conversion from immediate- to extended-release carbamazepine

Area of Science:

• Pharmacology
• Neurology
• Drug Delivery Systems

Background:

• Narrow therapeutic ratio (NTR) antiepileptic drugs require precise dosing for optimal efficacy and safety.
• Drug concentration oscillations can lead to increased central nervous system (CNS) side effects.
• Carbamazepine (CBZ) is an antiepileptic drug often associated with tolerability issues due to its absorption profile.

Purpose of the Study:

• To evaluate if switching from immediate-release carbamazepine (IR-CBZ) to extended-release carbamazepine (ER-CBZ) reduces CNS side effects.
• To assess the impact of uniform drug delivery on the tolerability of carbamazepine.
• To correlate formulation-specific absorption variability with CNS side effect incidence.

Main Methods:

• A comparative study involving 61 patients with partial-onset seizures.
• Patients were treated with IR-CBZ for at least one year, followed by a switch to ER-CBZ for at least one year.
• Central nervous system (CNS) side effects, seizure frequency, and formulation absorption variability were analyzed.

Main Results:

• The incidence of CNS side effects decreased from 49% with IR-CBZ to 20% with ER-CBZ.
• Improved tolerability was observed with ER-CBZ, particularly at higher daily doses (≥1200 mg).
• Pharmacokinetic analysis revealed significantly higher absorption and drug concentration variability with the IR-CBZ formulation.

Conclusions:

• Extended-release carbamazepine (ER-CBZ) formulations offer improved CNS tolerability compared to immediate-release carbamazepine (IR-CBZ).
• Smoother drug delivery and less variable absorption from ER-CBZ contribute to enhanced patient tolerability.
• Uniform drug delivery is a key factor in managing tolerability for narrow therapeutic ratio antiepileptic drugs.